Drug-drug interactions of simnotrelvir/ritonavir: an open-label, fixed-sequence, two-period clinical trial - Ye, Pan-Pan; Yao, Bu-Fan; Yang, Yang; Yang, Xin-Mei; Li, Qian; Song, Lin-Lin; Chen, Ke-Guang; Zhou, Hai-Yan; Shi, Jin-Yi; Zhang, Ye-Hui; Zhao, Fu-Rong; Guo, Zi-jia; et al. (Clinical microbiology and infection, 2025)
Keywords: Adult; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A - metabolism; Cytochrome P-450 CYP3A Inhibitors - pharmacology; Drug Combinations; Drug Interactions; Drug-drug interaction; Female; Healthy subjects; Humans; Itraconazole - adverse effects; Itraconazole - pharmacology; Male; Midazolam - adverse effects; Midazolam - pharmacokinetics; Middle Aged; Pharmacokinetics; Rifampin - adverse effects; Ritonavir - adverse effects; Ritonavir - therapeutic use; Safety; Simnotrelvir; Young Adult; Simnotrelvir; Healthy subjects; Safety; Drug-drug interaction; Pharmacokinetics